Oxford Biomedica has paired record new-client signings with reiterated revenue guidance, but its first-half numbers also showed a widening loss, a lower gross margin and a sharp fall in cash.
Oxford Biomedica (LSE:OXB), the viral vector contract development and manufacturing organisation known as OXB, has spent the weeks since its 22 September interim results setting out how it plans to turn a fast-growing order book into profit. The half-year statement covering the six months to 30 June 2026 showed revenue of £79.8m, up 9% on the £73.2m reported a year earlier, or 10% at constant currency. Manufacturing services were the main engine, rising 20% to £43.1m, while development services edged up 1% to £27.1m. Licence, milestone and royalty income fell to £1.2m as royalties from the maturing Kymriah product declined.
Commercial momentum versus margin pressure
The headline commercial message was solid. OXB said it signed 17 new clients in the first half, more than 30% above its total for all of 2025, with a further four added after the period end. Its book now spans 50 clients and 59 programmes, compared with 37 clients and 44 programmes in September 2025, and includes six late-stage clinical programmes and three commercial agreements. Contracted orders of about £97m were signed during the half, and the company put its non-risk-adjusted new business pipeline at roughly $713m, around 30% higher year on year. Approximately £168m of forecast 2026 revenue was already covered by contracted orders.
Profitability moved the other way. Gross profit slipped to £29.1m and gross margin narrowed to 37% from 43%, which management attributed to product and client mix and one-off items in the comparative period. Adjusted operating EBITDA was a loss of £2.5m, an improvement on the £3.9m loss a year earlier, but the operating loss widened to £29.1m, partly reflecting a £7.6m impairment on French property, plant and equipment linked to lower near-term revenue expectations there. The net loss for the half was £37.0m.
Cash, sites and guidance
Cash fell to £75.3m at 30 June from £96.9m at the end of 2025, and stood at £66.8m by 31 August. Net cash was £21.4m, down from £55.4m, after an operating outflow of £34.3m driven by financing costs and working capital. The company drew $15m under its Oaktree facility in March. Its going-concern review said cash was sufficient for at least 12 months under base and mitigated downside cases, while noting that if base-case cash flows did not materialise, mitigating actions such as reduced investment, site rationalisation and workforce cuts could begin by the end of the fourth quarter of 2026.
Operationally, OXB said the six-month delay to good manufacturing practice (GMP) readiness at its Durham, North Carolina site had been resolved, with the first GMP run completed and client activity expected to ramp up in the second half. GMP suites in France are fully qualified, and manufacturing has moved from Bedford, Massachusetts, to Durham.
Guidance was reiterated in full. OXB expects 2026 constant-currency revenue of £180m–£200m, revenue growth of 25%–30% in each of 2027 and 2028, an EBITDA margin of at least double digits in 2027 and an ambition of about £500m of revenue by 2030.
Recent filings
Since the results, the company's regulatory news has been routine. On 9 October it reported the admission of 5,654 shares issued under its long-term incentive plan, taking the total admitted to 121,050,158. A 6 October filing showed a senior US employee exercising restricted stock units and selling 1,167 shares at £5.518. Chief executive Dr Frank Mathias described the first half as commercially solid, highlighting record client wins.
For the FTSE 250 group, the coming months will test whether the expanded client base converts into the second-half revenue weighting its guidance requires.






Please wait processing your request...